ARNA - Arena Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Arena Pharmaceuticals, Inc.

6154 Nancy Ridge Drive
San Diego, CA 92121
United States
858-453-7200
http://www.arenapharm.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees159

Key Executives

NameTitlePayExercisedYear Born
Mr. Kevin R. LindCFO & Exec. VP342.33kN/A1976
Mr. Steven W. SpectorExec. VP, Gen. Counsel and Sec.638.3kN/A1965
Mr. Vincent E. AurentzChief Bus. Officer & Exec. VP274.24kN/A1968
Dr. Preston S. KlassenChief Medical Officer and Exec. VP of R&DN/AN/A1969
Mr. Amit D. MunshiChief Exec. Officer, Pres and Director644.43kN/A1968
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel small molecule drugs for various therapeutic areas in the United States and Switzerland. Its proprietary investigational clinical programs include ralinepag (APD811), which is in Phase III trial to treat pulmonary arterial hypertension; etrasimod that is in Phase II trials for treating immune and inflammatory conditions with primary focus on ulcerative colitis and hepatic conditions, as well as for primary biliary cholangitis and pyoderma gangrenosum; and APD371, which is in Phase II trial for the treatment of pain associated with Crohn's disease. The company has collaboration agreements with Everest Medicines Limited; Axovant Sciences GmbH; Boehringer Ingelheim International GmbH; Eisai Co., Ltd.; and Eisai Inc. Arena Pharmaceuticals, Inc. was founded in 1997 and is based in San Diego, California.

Corporate Governance

Arena Pharmaceuticals, Inc.’s ISS Governance QualityScore as of August 1, 2018 is 3. The pillar scores are Audit: 2; Board: 1; Shareholder Rights: 3; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.